Healthcare Wire Texas
SEE OTHER BRANDS

Exploring the health and wellness news of Texas

Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on June 4, 2025

TTUHSC Professor and Surgeon Receives National Award

TTUHSC Professor and Surgeon Receives National Award

John A. Griswold, M.D., Honored by ABA for Lifetime Achievements LUBBOCK, TX, UNITED STATES, June 4, 2025 /⁨EINPresswire.com⁩/ -- The American Burn Association (ABA) recently presented the prestigious Lifetime Achievement Award to Texas Tech University …

First Comprehensive Chest Pain Centers certified in India

First Comprehensive Chest Pain Centers certified in India

The American Heart Association recognizes three hospitals for excellence in cardiac emergency care DALLAS, TX, UNITED STATES, June 4, 2025 /⁨EINPresswire.com⁩/ -- Cardiovascular disease (CVD) is a leading cause of death worldwide, including in India, …

L. Fitzgerald Stills Releases 'It’s Time to Rewrite Your Story' – A Call to Divine Purpose

L. Fitzgerald Stills Releases 'It’s Time to Rewrite Your Story' – A Call to Divine Purpose

Stills offers a faith-driven guide to discovering purpose, breaking spiritual stagnation, and embracing Kingdom living. HOUSTON, TX, UNITED STATES, June 4, 2025 /⁨EINPresswire.com⁩/ -- L. Fitzgerald Stills, a devoted servant of Christ with over thirty …

National Assn. of Worksite Health Centers Rebrands as 'National Assn. for Workplace Health Care'

National Assn. of Worksite Health Centers Rebrands as 'National Assn. for Workplace Health Care'

NAWHC changes its name to reflect expanded scope beyond worksite centers to include direct contracting for medical services. DALLAS, TX, UNITED STATES, June 4, 2025 /⁨EINPresswire.com⁩/ -- The National Association of Worksite Health Centers (NAWHC) has …

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application …

Covasant Technologies Partners With Botminds to Help Global Enterprises Accelerate Agentic AI Adoption

Covasant Technologies Partners With Botminds to Help Global Enterprises Accelerate Agentic AI Adoption

Covasant …

Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit – United for Progress: A New Chapter in Sarcoidosis

Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit – United for Progress: A New Chapter in Sarcoidosis

CHICAGO, June 04, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding a cure for sarcoidosis and improving patient support, is proud to announce the 2025 FSR Global Virtual …

Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco

Sutter Health Breaks Ground on $442 Million Neuroscience Complex in San Francisco

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to high-quality neurological and neurosurgical care in Northern …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

                                                        Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) …

Information relative au nombre total des droits de vote et  d’actions composant le capital social au 30 mai 2025

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025

                                                                                                                                                                                                                                        Information relative au …

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

SI-BONE to Truist Securities MedTech Conference on June 17, 2025

SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech …

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast …

NeuroPace Secures Up to $75 Million in Debt Financing

NeuroPace Secures Up to $75 Million in Debt Financing

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit …

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its …

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people …

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, …

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living …

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

TORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service